bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.10.02.677497

Isolation, Identification and Determination of Antibiogram Characteristics of Escherichia Coli from Calves in West Shewa Zone, Oromia, Ethiopia.

Abstract

A cross-sectional study, conducted from December 2022 to April 2024 in West Shewa, Oromia, Ethiopia aimed to isolate and identify Escherichia coli from calves and determine its antimicrobial susceptibility patterns. Diarrheic calves were purposively sampled, while non-diarrheic calves were randomly sampled. Escherichia coli was isolated using standard bacteriological methods. Stx1 and eaeA virulence genes were detected by PCR. Escherichia coli susceptibility to 11 antibiotics was assessed via disk diffusion. The study data was analyzed using SPSS version 20. A total of 162 rectal fecal samples were collected 84 from diarrheic calves and 78 from non-diarrheic calves aged 0-4 months. Escherichia coli was isolated in 48.1% (78/162; 95% CI: 40.2-56.1%). Escherichia coli was more common in diarrheic calves (56%) than non-diarrheic ones (40%) (p = 0.039). Season, age, health, house hygiene, first colostrum feeding, and feeding technique all significantly impact on the occurrence of Escherichia coli (p < 0.05). 10 of the 78 isolates were PCR-tested for eaeA and stx1 genes. The PCR results showed 30% had eaeA, 60% had stx1, and 10% had both genes. Isolates from diarrheic (n=24) and non-diarrheic (n=16) calves showed resistance to ampicillin, amoxicillin, tetracycline, and amoxicillin/clavulanic acid, but were susceptible to gentamicin, norfloxacin, nitrofurantoin, and streptomycin. The 54.2% of isolates from diarrheic calves and 50% from non-diarrheic calves were multidrug resistant. It was concluded that Escherichia coli may cause calf diarrhea, influenced by season, age, health, and colostrum feeding timing. The effective antibiotics identified were gentamicin, nitrofurantoin, norfloxacin, and streptomycin. Further characterization of Escherichia coli in calves is needed to improve calf health and antibiotic stewardship.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Deressa, L. C.. 2025-10-06. Isolation, Identification and Determination of Antibiogram Characteristics of Escherichia Coli from Calves in West Shewa Zone, Oromia, Ethiopia.. https://doi.org/10.1101/2025.10.02.677497

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗